The Smash Childhood Cancer (SCC) team shared an update as they continue to validate results.
The Smash Chilldhood Cancer (SCC) project aims to find the best drugs that target key molecules in childhood cancers. World Community Grid volunteers across the globe have contributed over 57 thousand CPU years to this project. Thanks to their help, the team has been able to design drugs for multiple types of cancer, such as neuroblastoma (cancer of nerve tissues), hepatoblastoma (liver cancer), osteosarcoma (bone cancer), and most recently, Ewing’s sarcoma.
SCC Research Update
Dr. Shefali Chauhan at cc-TDI continues to validate 3 new compounds from CREB1 modeling studies that have cross-specificity for FLI1, the structured half of the EWSR1::FLI1 protein in Ewing sarcoma. Nikita Rozanov at cc-TDI and Dr. Tyuji Hoshino at Chiba University are processing hits for Brachyury (chordoma), FLI1 (Ewing sarcoma), KLF15 (myoepithelial carcinoma) and MyoD1 (sclerosing and spindle cell rhabdomyosarcoma), which Dr. Chauhan and colleagues will then validate. Dr. Charles Keller has recently submitted additional work on PAX3/7::FOXO1, now funded by NIH, as preliminary data for a $25M Cancer Research UK - NCI Grand Challenge in collaboration with Nurix Therapeutics and a network of academic collaborators.
Thank you to the SCC team for sharing this update with us. For the time being, no SCC work units will be available as the team focuses on validations from the earlier run. If you have any questions or comments, please leave them in this thread for us to answer.